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There are estimates of oral aluminum (Al) bioavailability from drinking water, but little 
information on Al bioavailability from foods. Foods contribute ~ 95% and drinking water 1 to 2% 
of the typical human’s daily Al intake. The objectives were to estimate oral Al bioavailability from 
a representative food containing the food additive acidic sodium aluminum phosphate (acidic 
SALP), a leavening agent in baked goods. Rats were acclimated to a special diet that resulted 
in no stomach contents 14 h after its withdrawal. They were trained to rapidly consume a biscuit 
containing 1.5% acidic SALP. Oral Al bioavailability was then determined from a biscuit 
containing 1 or 2% acidic SALP, synthesized to contain 26Al. The rats received concurrent 27Al 
infusion. Blood was repeatedly withdrawn and serum analyzed for 26Al by accelerator mass 
spectrometry. Total Al was determined by atomic absorption spectrometry. Oral 26Al 
bioavailability was determined from the area under the 26Al, compared to 27Al, serum 
concentration × time curves.  
Oral Al bioavailability (F) from biscuit containing 1 or 2% acidic 26Al-SALP averaged ~ 
0.11 and 0.13%; significantly less than from water, which was previously shown to be ~ 0.3%. 
The time to maximum serum 26Al concentration was 4.2 and 6 h after consumption of biscuit 
containing 1 or 2% 26Al-acidic SALP, respectively, compared to 1 to 2 h following 26Al in water.  
These results of oral Al bioavailability from acidic 26Al-SALP in a biscuit (F ~ 0.1%) and 
results from 26Al in water (F ~ 0.3%) × the contributions of food and drinking water to the typical 
human’s daily Al intake (~ 5 to 10 mg from food and 0.1 mg from water, respectively) suggest 
food provides ~ 25-fold more Al to systemic circulation, and potential Al body burden, than does 





Keywords: Accelerator mass spectrometry; Acidic sodium aluminium phosphate; Aluminum; 
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1. Introduction  
Aluminum (Al) can produce toxicity to the central nervous, skeletal and hematopoietic 
systems. It can produce an encephalopathy in renal-impaired humans (dialysis 
encephalopathy), cognitive deficits in young children, a low-turnover bone disease, a microcytic 
hypochromic anemia, and has been controversially implicated as an environmental factor that 
may contribute to some neurodegenerative diseases, including Alzheimer’s disease (Alfrey et 
al., 1976; Bushinsky, 1997; Yokel, 2000; Gupta et al., 2005; Kawahara, 2005). 
The primary oral source of Al in the U.S. for the typical human is foods, contributing ~ 5 
to 10 mg of Al daily, whereas drinking water provides ~ 0.1 mg of Al (Yokel and McNamara, 
2001). Different food sources contribute variable amounts of Al to the human diet (Pennington, 
1987; UK MAFF, 1993; Lopez et al., 2002). FDA-approved, generally recognized as safe 
(GRAS) (21 CFR 121.1), food additives are the major source of dietary Al in the U.S. They 
increase the low inherent level of Al in food by about five-fold (Humphreys and Bolger, 1997). 
The approved uses of Al as a food additive in the U.S., Canada and the U.K. are as firming 
agents, carriers, coloring agents, anti-caking agents, buffers, neutralizing agents, dough 
strengtheners, emulsifying agents, stabilizers, thickeners, leavening agents, curing agents and 
texturizers (UK MAFF, 1993; Nieboer et al., 1995). These additives are approved for use in milk, 
processed cheese, yogurt, preserves, jams and jellies, baking soda, sugars, cereals, flours, 
grains and powdered or crystalline desert products (Nieboer et al., 1995). The two most 
quantitatively significant food additives containing Al are acidic sodium aluminum phosphate 
(SALP; a leavening agent in baked goods) and basic SALP (an emulsifying agent in processed 
cheese) (Katz et al., 1984; Humphreys and Bolger, 1997; Saiyed and Yokel, 2005). Surveys of 
daily dietary Al intake suggested adults in the U.S. consumed ~ 7 to 9 mg Al daily, depending 
on age and sex (Pennington and Schoen, 1995) and adults in the U.K. consumed 3.9 mg Al 
daily (UK MAFF, 1993). There have been ~ 12 estimates of dietary Al consumption by adults 
published in the past 10 years from other countries. Most reported equal or less daily Al intake 
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than in the U.S. The lower daily Al intakes in some countries, such as in Europe, have been 
attributed to less use of Al as a food additive (Müller et al., 1998).  
The oral bioavailability of Al has been estimated in a number of studies. The primary 
interest has been to model drinking water Al consumption and to determine the effect of citrate 
and silicate on oral Al bioavailability. These are briefly reviewed in the Discussion. It has been 
suggested that Al bioavailability from water is greater than from food (Martyn et al., 1989). The 
proposed basis for this is the presence of organic ligands such as phytates and polyphenols in 
food that are suggested to complex Al and inhibit its oral absorption.  
The extent of oral absorption (bioavailability) of hydrophilic substances is generally 
determined by a comparison of areas under the concentration (AUC) × time curve for the test 
substance given po and iv. This can be accomplished when the test substance is given as two 
analytically distinguishable, but biologically indifferent, chemical species at the same time by the 
po and iv routes. This was the method employed in the present study to estimate oral Al 
bioavailability from a model food, a biscuit, which contained acidic SALP that was prepared with 
26Al as a tracer. 26Al was analyzed by accelerator mass spectrometry (AMS). The use of 26Al in 
the study of Al toxicokinetics has been reviewed (Flarend and Elmore, 1998). As there is no 
measurable 26Al in the environment or in normal biological organisms, this approach avoids the 
interference of endogenous Al in the study of Al pharmacokinetics. AMS measures the ratio of 
26Al compared to 27Al with a detection limit of 26Al/27Al of ~ 10− 14. In the presence of 4 mg 27Al, 
as used in the present study, this represents ~ 4 × 10− 17 g of 26Al, or ~ 1,000,000 atoms. 
Therefore, by utilizing 26Al analyzed by AMS, pharmacokinetic studies of Al can be conducted at 
physiological concentrations. As there are negligible chemical differences between 26Al and 27Al 
they should be handled indistinguishably in vivo. This presents the opportunity to concurrently 
administer two Al isotopes and differentially analyze them in the same sample utilizing AMS for 
26Al and electrothermal atomic absorption spectrometry for 27Al, when 26Al provides an insignifi-
cant contribution to total Al. This approach was used in the present study. 
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2. Methods  
2.1. Materials 
Details of the preparation and characterization of the acidic SALP containing 26Al (acidic 
26Al-SALP) were described (Yokel et al., 2005). 26Al was provided by the Purdue Rare Isotope 
Measurement Laboratory (PRIME Lab), supplied in 0.01 N HCl containing 8.25 nCi (434 ng) 
26Al/ml and with a 34:1 27Al:26Al ratio yielding 15.2 µg total Al/ml. Briefly, Al(OH)3 containing 26Al 
was prepared and was characterized by near infrared spectroscopy.  It was incorporated into 
the synthesis of acidic SALP by the method of McDonald (1951). The acidic SALP was 
characterized by near infrared spectroscopy; x-ray powder diffraction spectroscopy; and 
elemental analysis of Na, Al and P. 
The acidic 26Al-SALP was incorporated into a biscuit, as 1 and 2% SALP. A baking powder 
containing 25% acidic-SALP, 25% sodium bicarbonate and 50% corn starch was prepared to 
model the typical acidic SALP content (21 to 26%) of baking powders (Pennington, 1987). This 
was incorporated into a biscuit, prepared from 90% wheat flour, 0.8% salt, 3% butter, 6% baking 
powder and water as necessary. The 26Al concentration in the biscuit was determined as 
follows. Biscuit (~ 20 to 25 mg) was transferred to 7 ml screw cap Teflon® Tuf-tainers® and 4 
mg Al (Aldrich ICP/DCP standard) added.  Samples were dried then digested in a 2:1 nitric 
acid:peroxide mixture.  The acid was then diluted 4 times, each a 10-fold dilution, and an aliquot 
transferred to a porcelain crucible and 4 additional mg of Al standard added.  The sample was 
then slowly heated to 1000 ºC in a muffle furnace to convert the Al to Al oxide.  The Al oxide 
was analyzed by AMS, as described below. The biscuit containing 1 and 2% acidic 26Al-SALP 
had 0.98 nCi (51.5 ng) or 1.02 nCi (53.6 ng) 26Al, respectively. An identical biscuit without 26Al, 
but containing ~ 1.5% acidic SALP, was similarly prepared to acclimate and train the rats, as 
noted below. 
 
2.2. Animals  
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The subjects were 13 male Fisher 344 rats, weighing 322 ± 32 g (mean ± SD). Animal 
work was approved by the University of Kentucky Institutional Animal Care and Use Committee. 
The research was conducted in accordance with the Guiding Principles in the Use of Animals in 
Toxicology.  
 
2.3. Experimental procedures  
The subjects were acclimated to a 10% protein diet that was designed to minimize food 
retention in the stomach (Harlan Teklad 95215). They had food access from 08:00 to 18:00 h 
daily for ≥ 5 days prior to the determination of oral Al bioavailability. This diet was shown to 
result in the absence of food in the stomach 14 h after its withdrawal when fecal recycling 
(coprophagia) was prevented by a fecal collection cup, as described (Yokel et al., 2001). In a 
pilot study, six rats had access to this diet for 10 h daily for 7 days. Fourteen h after diet 
removal, no food was found in their stomachs (Yokel et al., 2001). Drinking water was freely 
available throughout the study except for the period from 14 h before to 4 h after oral dosing. 
The rats were conditioned to eat 1 g of biscuit containing ~ 1.5% acidic SALP without 
26Al which was presented 14 h after diet removal daily for ≥ 4 days. Rats that learned to readily 
eat the food within 15 min were surgically prepared with venous cannulae to enable blood 
withdrawal. They were implanted with two femoral venous cannulae 1 day prior to oral dosing. 
This enabled iv administration through one cannula and blood withdrawal from another, to avoid 
contamination of withdrawn blood by the administered Al. Precise food consumption was 
determined by pre-weighing the presented biscuit (to obtain its dry weight) then rigorously 
recovering from the rat’s cage 30 min later the uneaten biscuit, which was dried and weighed. 
Oral bioavailability calculations were based on the weight of consumed biscuit. 
Addition of 1 and 2% acidic SALP to biscuit was selected to provide two amounts of Al to 
ascertain if there was dose-dependent absorption and to stay within the maximum use level of 
2.5% for acidic SALP as a leavening agent in baked goods (Pennington, 1987). These 
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concentrations were similar to those found in some baked goods or baked good mixes, that had 
up to 1200 mg Al/kg, equivalent to ~ 1.4% acidic SALP (Saiyed and Yokel, 2005). 
The subjects were randomly assigned to be given 1 g biscuit containing 1 or 2% acidic 
26Al-SALP (n = 5/group), in the absence of food in the stomach. Two control rats similarly 
received biscuit containing 1.5% acidic SALP and one rat received intragastric administration of 
1 ml of water, without 26Al. 
Oral Al bioavailability was determined in the un-anesthetized rat. Based on the results of 
a pilot study, the rats were iv infused at 100 µg Al/kg/h to produce an estimated 500 µg Al/l in 
blood plasma for the 27Al dose, as described (Yokel et al., 2001). In this study AlK(SO4)2 was 
continuously infused from 14 h prior to 60 h after oral dosing. Blood was withdrawn 1 h prior to 
and 0, 1, 2, 4, 8, 24, 36, 48 and 60 h after oral dosing. These sample times were based on two 
similar studies in which rats were given oral Al solution. In the initial study blood samples were 
obtained to 120 h. However, only two samples beyond 24 h met the criteria to be reliably above 
pre-treatment serum values. Therefore, the results are essentially based on samples up to 24 h 
(Yokel et al., 2001). In the second study blood samples were obtained to 24 h (Zhou and Yokel, 
2006). The sampling times of the present study included 36, 48 and 60 h, based on the 
expectation that Al absorption from a solid food would be more prolonged than from water. The 
blood withdrawn (0.3 ml for the -1 to 4 h samples, then 0.5 ml for the 8 h sample, 2.1 ml at 24 h 
and 4.1 ml at 36 and 48 h), was replaced by an equal volume of injected saline. Additionally, the 
rats had access to 2 ml water with the biscuit and free water and food (10% protein diet) 
beginning 4 h after dosing. The 60 h blood sample was obtained by anesthetizing the rat and 
exsanguination from a femoral cannula and then the heart.  Serum was obtained for 26Al and 
27Al analysis. Blood urea nitrogen (BUN) and creatinine were determined in the 60 h sample.  
 
2.4. Analysis of total Al by electrothermal atomic absorption spectrometry   
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A pooled serum sample from untreated rats was rigorously analyzed by the method of 
additions to determine its 27Al content. Standards containing Al were prepared from aliquots of 
this sample, diluted 10-fold with 0.2% HNO3 and 2.5 mM Mg and spiked with known amounts of 
a commercial analytical 27Al standard. Samples were similarly prepared and analyzed compared 
to the standards, using a Perkin-Elmer 4100 ZL transversely heated graphite atomizer atomic 
absorption spectrophotometer vented to the outside air to avoid laboratory contamination with 
26Al. Standard curves were obtained before and after every ten samples. An aliquot of each 
serum sample was diluted at least 10-fold, as above, prior to analysis. All post-26Al-treatment 
serum samples were repeatedly analyzed until their Al concentration RSD was < 10%, as 
previously conducted (Yokel et al., 2001).  
 
2.5. Analysis of 26Al by accelerator mass spectrometry (AMS)  
The procedures were as described by Yokel et al. (2001).  
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2.6 Data analysis  
A criterion for acceptance of post-treatment serum 26Al concentrations 
considered to be reliably above pre-treatment serum values was established as > 2 SD 
above the mean pre-treatment serum 26Al concentration. This criterion was 0.31 pg 26Al/l. 
Values below this criterion are not presented graphically and were not used in the data 
analysis. This criterion was met by all of the samples obtained except one value at 48 h 
and one at 60 h; both were 0.3 pg 26Al/l. The mean half-life of elimination of the 26Al, 
determined using RSTRIP (Fox and Lamson, 1989), was 4.8 h. Therefore, blood was 
obtained for > 3 half-lives, which is more than sufficient time to determine the AUC of the 
26Al. Each subject’s pre-treatment serum 26Al concentration was subtracted from its post-
treatment values. Oral 26Al bioavailability (F) was calculated as follows and expressed as 
a percent: 
The sum of the trapezoidal areas for 26Al            27Al hourly infusion rate × time 
The sum of the trapezoidal areas for 27Al                                    26Al dose 
 
 
Time to maximum serum 26Al concentration (Tmax) and the maximum concentration 
(Cmax) were calculated using RSTRIP. 
Unpaired two-tailed t-tests were used to test for differences in the oral bioavailability, 
Tmax and Cmax of Al from the 1% compared to 2% acidic SALP and from the combined acidic 
SALP results compared to results of Al absorption from water, which was previously conducted 
(Yokel et al., 2001; Zhou and Yokel, 2006). For results with significantly different variances a 





× F = 
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3. Results  
The rats given biscuit containing 26Al-SALP consumed 0.35 to 1.04 gm (mean = 0.70). 
Each rat’s serum 26Al results were normalized to its 26Al dose. The BUN and serum creatinine 
values of the rats in this study ranged from 7.4 to 17.8 and from < 0.2 to 0.4 mg/dl, respectively, 
well within normal limits (< 30 and 1 mg/dl, respectively). The 26Al concentration in the serum 
samples obtained from all rats prior to 26Al (or 26Al vehicle) dosing ranged from 0 to 0.4 (mean = 
0.085) pg/l. The concentration of 26Al in the 8 samples from each of the three non-26Al-treated 
rats after vehicle dosing ranged from 0 to 0.6 pg/l (mean = 0.11). Therefore, serum from non-
26Al-treated rats did not show appreciable cross-contamination. Peak serum 26Al concentrations 
after oral 26Al dosing in 1% acidic SALP ranged from 36.5 to 93.6 pg/l and after 2% acidic SALP 
from 13.9 to 156.3 pg/l. Therefore, the oral 26Al dose increased peak serum 26Al ~ 160- to 1840-
fold above mean pre-treatment values. The time courses of serum 26Al following oral 26Al dosing 
for the two acidic SALP treatment groups are shown in Figure 1. In the 1% SALP group peak 
serum 26Al concentration occurred in the 2 h sample from one rat, the 4 h sample from three 
rats, and the 8 h sample from one rat. In the 2% SALP group peak serum 26Al concentration 
was seen in the 2 h sample from one rat, the 4 h sample from two rats, and the 8 h sample from 
two rats. The percentage of the AUC included in the AUCtime to last sample/AUCinfinity was > 95% in all 
cases, indicating that samples were collected for sufficient time to adequately determine oral Al 
absorption. Oral Al bioavailability and the results of RSTRIP analysis of Tmax and Cmax are shown 
in Table 1. The differences in Al bioavailability, Tmax and Cmax results from 1% compared to 2% 
acidic SALP were not statistically significant. The differences in these measures from the 
combined 1% and 2% acidic SALP data compared to the individual or combined Al 
bioavailability data from studies of Al absorption from water (Yokel et al., 2001; Zhou and Yokel, 
2006) were significant.  
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4. Discussion  
There has been some controversy about the safety of Al in food for nearly a century. 
Gies (1911) concluded from available studies that the use of Al in food was a dangerous 
practice. For substances used in foods prior to 1958, the FDA permits expert opinion to be 
based on a reasoned judgment founded in experience with common food use, taking into 
account reasonably anticipated patterns of consumption, cumulative effects in the diet, and 
safety factors appropriate for the utilization of animal experimentation data (FASEB, 1975). A re-
review of the GRAS status of Al was conducted, based on the previous review, a review of the 
published literature, and studies contracted by producers of acidic SALP which was fed to rats 
and dogs in diets containing up to 3% for 90 days (FASEB, 1975). The opinion of the FASEB 
members who conducted the review was that “There is no evidence in the available literature on 
…acidic sodium aluminum phosphate [and other Al forms] … that demonstrates, or suggests 
reasonable grounds to suspect, a hazard to the public when they are used at levels that are now 
current or that might reasonably be expected in the future.”  Although noting that care should be 
taken by patients with kidney disease when consuming food containing high levels of Al salts, 
the authors did not mention dialysis encephalopathy, which has been attributed to Al, or the 
controversial role of Al in Alzheimer’s disease. Indeed, the contribution of Al from Al cooking 
utensils to serum Al and urinary Al excretion in patients with chronic renal insufficiency has been 
demonstrated (Lin et al., 1997). 
A central issue in the controversy concerning the safety of Al in foods is its oral 
bioavailability. This is the first study to determine oral Al bioavailability from a common specific 
food component that provides a significant contribution to dietary Al intake. 
There have been previous studies addressing the ability of acidic SALP to produce 
toxicity and to be absorbed. A study conducted by the Stauffer Chemical Company failed to find 
significant toxicity from acidic SALP (Levair, now marketed by Rhodia) when added to the diet 
of beagles for six months, at 0.1 and 3% of the diet. Although females experienced some 
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statistically significant reductions in food intake, they were not considered toxicologically 
significant because there was no corresponding weight reduction. Diagnostic histopathology 
showed no adverse outcomes (Katz et al., 1984). This study did not determine Al bioavailability 
or blood or tissue Al concentrations. Oral absorption of Al from a food was demonstrated in 
guinea pigs that ate a sponge cake containing acidic SALP. It provided 376 µg Al/g; a total of 40 
mg of Al over 3 weeks. They had a significant elevation of bone Al compared to subjects eating 
only guinea pig chow (Owen et al., 1994).  
It might be anticipated that some Al consumed in food would be solubilized in the low pH 
of the stomach. This was found in studies of the solubility of Al compounds contained in bread in 
normal human subject stomach contents, according to Steel (1911) and Smith (1928). Over 
75% of the Al in corn bread baked with corn having 0.2% Al was extracted using 0.3% HCl at 37 
ºC for 12 h (Myers and Voegtlin, 1914). Approximately 25% of the Al from Al baking powders 
used to prepare ~ 100 g of biscuit that was eaten by humans was found in a soluble form in the 
stomach and duodenal contents (Gies, 1911; Myers and Killian, 1928). Soluble Al in the 
stomach (at pH 1.3 to 1.6) and intestine (at pH 8.1 to 8.4) of guinea pigs that consumed sponge 
cake containing acidic SALP was 17 and 0.3% of the total Al, respectively (Owen et al., 1994). 
Using an in vitro simulated gastrointestinal digestion procedure to estimate the absorbable 
fraction of Al from foods, Lopez et al. (2002) concluded it to be 0.85 to 2.15% from various 
foods.  The solubility of Al in the stomach was also suggested based on Al chemistry, as Al 
becomes a free ion, with waters of hydration, below pH 5, in the absence of complexing ligands 
(Harris et al., 1996). As Al forms insoluble Al hydroxide at circum-neutral pH, it may precipitate, 
inhibiting absorption, when it enters the intestines, as suggested by Reiber et al. (1995). 
Therefore, it is difficult to predict the extent of oral Al bioavailability. The anticipated low 
bioavailability of Al from food, based on its low bioavailability from water, makes determination 
of oral absorption difficult. In light of the ubiquitous presence of Al in the environment and 
biological organisms, it would require a considerable increase of Al from absorption, and large 
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oral exposure, to reliably see an elevation above the background Al concentration. The use of 
26Al and AMS in the present study overcomes this problem. 
There have been prior attempts to address oral Al bioavailability from foods. Studies 
showed measurable amounts of Al in the blood of dogs fed alum (AlK(SO4)2) in “meat-hash pills” 
and biscuits baked with alum baking powder, but not in non-Al fed dogs (Steel, 1911). Similarly, 
dogs fed a few biscuits containing sodium aluminum sulfate, in the absence or addition of mono 
calcium phosphate, often had more Al in their blood and tissues than dogs consuming a normal 
diet (Underhill and Peterman, 1929a). Some humans also showed small increases of Al in blood 
and urine after consumption of biscuit or griddle cake containing commercial “alum phosphate” 
baking powder (Underhill and Peterman, 1929b). On the other hand, only a slight increase of 
tissue Al was seen in rats that consumed ~ 8 mg Al/kg daily in biscuit (Myers and Mull, 1928). A 
review of balance studies in humans concluded they were not able to determine oral Al 
bioavailability from foods, because the percentage absorbed is so low (UK MAFF, 1993). Al 
bioavailability from diets containing ~ 5 mg Al daily was estimated, based on urinary Al excretion 
compared to dietary Al intake, to be 0.78% in young human males. When Al lactate was added 
to the diet to provide 120 mg Al/day, a similar calculation suggested ~ 0.09% Al absorption 
(Greger and Baier, 1983). Stauber et al. (1999) estimated Al bioavailability from drinking water 
and food in humans and found it comparable from these two sources, ~ 0.3%. Al bioavailability 
from food was based on 24 h urinary Al excretion during the second day of consumption of a 
controlled diet. This diet provided ~ 3 mg Al/day, below typical dietary intake. Absorption of Al 
from food consumed prior to the study, which likely provided > 3 mg Al/day, may have 
contributed to the urinary Al excretion during the study because < 50% of Al excreted in the 
urine after 26Al administration appears within the first 24 h (Priest, 1993; Talbot et al., 1995). 
Therefore Stauber et al. may have over-estimated dietary Al bioavailability. Oral Al 
bioavailability from food has been estimated to be ~ 0.1% based on average daily urinary Al 
excretion compared to average daily Al intake from food (Powell and Thompson, 1993; Priest, 
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1993; Nieboer et al., 1995). The results of the present study are consistent with previous total 
diet studies and estimates. 
The present study did not find an effect of the Al dose on Al bioavailability, within the 
range of acidic SALP-concentrations tested. The few studies conducted to date to address the 
possibility that Al bioavailability is dose-dependent have not resulted in consistent findings. 
The later Tmax of Al from acidic SALP in biscuit observed in the present study, compared 
to water, is consistent with the apparent site of Al absorption, the upper intestine and delayed 
gastric emptying of food compared to water (Froment et al., 1989; Nagy and Jobst, 1994; 
Whitehead et al., 1997). Cmax values were lower after oral consumption of 26Al in biscuit than 
water, as expected when oral bioavailability is lower and Tmax is later. 
The present estimate of oral Al bioavailability from a dietary component suggests lower 
oral Al bioavailability from food than previously reported in studies of water. In a study of 21 
humans the estimated oral bioavailability of 27Al, present in water from a municipal water 
treatment facility, was 0.36% (Stauber et al., 1999). Two studies, each conducted in two 
humans and utilizing 26Al, estimated oral Al bioavailability to be 0.1 and 0.22%, respectively 
(Hohl et al., 1994; Priest et al., 1998). These studies determined oral Al absorption from urinary 
Al excretion. Priest et al. (1998) and Stauber et al. (1999) attempted to correct their estimate of 
Al oral bioavailability for the fraction of absorbed Al that was not thought to be excreted in the 
urine during the duration of their studies. In a study in rats given intragastric 26Al in the absence 
and presence of food in the stomach, and with or without added calcium and magnesium to 
model hard drinking water, oral Al bioavailability averaged 0.28% (Yokel et al., 2001). A 
replication of this study, in the absence of food in the stomach or added calcium and 
magnesium to the water, showed oral Al bioavailability to be 0.29% (Zhou and Yokel, 2006).  
In summary, the bioavailability of Al from this representative food was significantly less 
than from water, when comparing studies using very similar experimental methods. The results 
of this study of oral Al bioavailability from acidic SALP in a biscuit suggest ~ 0.1% of the Al was 
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orally absorbed. A prior study and a recent replication of that study, using the same methods 
(Yokel et al., 2001; Zhou and Yokel, 2006), suggested ~ 0.3% of Al was orally absorbed from 
water. As noted in the Introduction, food and water provide ~ 5 to 10 mg and 0.1 mg of Al, 
respectively, to typical daily Al intake by humans. The products of their Al contribution to the diet 
× the absorbed percentage of Al (for food: 5 to 10 mg of Al × 0.1% absorption, delivering 7.5 µg 
of Al to systemic circulation daily; for water: 0.1 mg Al daily × 0.3% absorption, delivering 0.3 
µg) suggest food provides ~ 25-fold more Al to systemic circulation than does drinking water. 
This suggests food provides considerably greater potential to contribute to an Al body burden 
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Table 1. Oral Al bioavailability when dosed as 1 or 2% acidic SALP in biscuit or in water, and 
absorption Tmax and Cmax. Values are mean ± SD 
 
       1% SALP  
       in biscuit 
       2% SALP 
        in biscuit        Water
a 
Sum AUC for po 26Al (pg/l/h) 767 ± 457  692 ± 554 b 4999 ± 1884 
5260 ± 1301 c 
Sum AUC for iv 27Al (µg/l/h) 33367± 32253 
 
18290± 9544 b 20363 ±  19668 
24959 ±  7377 
Oral Al bioavailability (%) 0.11 ± 0.11 0.13 ± 0.12 b 0.28 ± 0.18 
0.29 ± 0.11 c 
Tmax (h) 4.2 ± 1.2 6.0 ± 1.7 b 1.7 ± 1.1  
1.2 ± 0.9 c 
Cmax (g/l serum) 54 ± 25 54 ± 42 b 584 ± 313 
659 ± 195 c 
Cmax (% of dose/ml serum) 0.00015 ± 0.000064 0.00012 ± 0.000082 b 0.00097 ± 0.00090  
0.0013 ± 0.0004 c 
a Results from (Yokel et al., 2001; Zhou and Yokel, 2006). These studies also used male Fisher 
344 rats; 19 weighing 280 ± 42 gm (Yokel et al., 2001) and 5 weighing 268 ± 18 gm (Zhou and 
Yokel, 2006). These results are based on samples collected 1, 2, 4, 8, 24, and (2 samples only) 
at 72 h (Yokel et al., 2001) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 4, 8 and 24 h after oral dosing 
(Zhou and Yokel, 2006). 
b Not significantly different from 1% SALP in biscuit results. 
c The results of each study and the combined results were significantly different from the 
combined results from 1 and 2% SALP in biscuit. 
 24 
Figure legend: 
Figure 1. Concentration of 26Al in serum versus time after consumption of 26Al that had been 
incorporated into acidic SALP which was included in a biscuit containing 1% (squares) or 2% 
(circles) acidic 26Al-SALP. The values are mean ± SD from 5 rats in each group.  
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Figure 1.  
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